181 related articles for article (PubMed ID: 21119195)
1. Pulmonary arterial hypertension: combination therapy in the modern management era.
Sitbon O
Eur Respir Rev; 2010 Dec; 19(118):348-9. PubMed ID: 21119195
[No Abstract] [Full Text] [Related]
2. Bosentan for the treatment of portopulmonary hypertension.
Tempe DK; Datt V; Datta D
Ann Card Anaesth; 2008; 11(2):139-40; author reply 140. PubMed ID: 18603763
[No Abstract] [Full Text] [Related]
3. Bosentan and sildenafil: should the combination therapy be a valid alternative in childhood to prostacyclin infusion?
Brancaccio G; Toscano A; Bevilacqua M; Di Chiara L; Parisi F
Pediatr Transplant; 2007 Feb; 11(1):110-2. PubMed ID: 17239133
[TBL] [Abstract][Full Text] [Related]
4. [Bosentan and chronic thromboembolic pulmonary hypertension].
Tomás C; Callejas-Rubio JL; Ríos-Fernández R; Ortego-Centeno N
Med Clin (Barc); 2007 Nov; 129(16):639. PubMed ID: 18001681
[No Abstract] [Full Text] [Related]
5. The management of Eisenmenger syndrome in the modern treatment era: a case report.
Gatzoulis MA
Eur Respir Rev; 2011 Dec; 20(122):293-6. PubMed ID: 22130823
[No Abstract] [Full Text] [Related]
6. Combination drug therapy in the management of pulmonary arterial hypertension.
Kayser SR
Prog Cardiovasc Nurs; 2005; 20(4):177-82. PubMed ID: 16276142
[No Abstract] [Full Text] [Related]
7. Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Chen YF; Jowett S; Barton P; Malottki K; Hyde C; Gibbs JS; Pepke-Zaba J; Fry-Smith A; Roberts J; Moore D
Health Technol Assess; 2009 Oct; 13(49):1-320. PubMed ID: 19863849
[TBL] [Abstract][Full Text] [Related]
8. Observational trials in pulmonary arterial hypertension: low scientific evidence but high clinical value.
Hoeper MM
Eur Respir J; 2007 Mar; 29(3):432-4. PubMed ID: 17329488
[No Abstract] [Full Text] [Related]
9. "Treat-to-target" in pulmonary arterial hypertension and the use of extracorporeal membrane oxygenation as a bridge to transplantation.
Hoeper MM
Eur Respir Rev; 2011 Dec; 20(122):297-300. PubMed ID: 22130824
[No Abstract] [Full Text] [Related]
10. [The combined use of sildenafil with epoprostenol in a patient with primary pulmonary hypertension].
Kayikçioğlu M; Can LH; Payzin S; Kültürsay H; Soydan I
Anadolu Kardiyol Derg; 2002 Sep; 2(3):262-4. PubMed ID: 12223337
[No Abstract] [Full Text] [Related]
11. [The treatment of idiopathic pulmonary artery hypertension and its relation to systemic scleroderma].
Humbert M
Rev Med Interne; 2007 Dec; 28 Suppl 4():S273-6. PubMed ID: 17961866
[No Abstract] [Full Text] [Related]
12. Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach.
Catapano-Minotti G; Corsonello A; Guadalupi G; Spani R; Antonelli-Incalzi R
Intern Med; 2008; 47(6):511-3. PubMed ID: 18344637
[TBL] [Abstract][Full Text] [Related]
13. [Treatment with sildenafil, bosentan, or both in children and young people with idiopathic pulmonary arterial hypertension and Eisenmenger's syndrome].
Raposo-Sonnenfeld I; Otero-González I; Blanco-Aparicio M; Ferrer-Barba A; Medrano-López C
Rev Esp Cardiol; 2007 Apr; 60(4):366-72. PubMed ID: 17521545
[TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
15. Consecutive use of sildenafil and bosentan for the treatment of pulmonary arterial hypertension associated with collagen vascular disease: sildenafil as reliever and bosentan as controller.
Kamata Y; Iwamoto M; Minota S
Lupus; 2007; 16(11):901-3. PubMed ID: 17971364
[TBL] [Abstract][Full Text] [Related]
16. Marked improvement with sildenafil in a patient with idiopathic pulmonary arterial hypertension unresponsive to beraprost and sarpogrelate.
Kawano H; Sengyoku H; Satoh O; Urabe S; Koide Y; Yano K
Intern Med; 2007; 46(12):893-8. PubMed ID: 17575385
[TBL] [Abstract][Full Text] [Related]
17. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension.
Mathai SC; Girgis RE; Fisher MR; Champion HC; Housten-Harris T; Zaiman A; Hassoun PM
Eur Respir J; 2007 Mar; 29(3):469-75. PubMed ID: 17079256
[TBL] [Abstract][Full Text] [Related]
18. Pulmonary arterial hypertension: the race for the most effective treatment.
McLaughin VV; Hoeper MM
Am J Respir Crit Care Med; 2005 Jun; 171(11):1199-201. PubMed ID: 15914567
[No Abstract] [Full Text] [Related]
19. Directing therapy in pulmonary arterial hypertension using a target 6 min walk distance.
Porhownik NR; Myers R; Bshouty Z
Can Respir J; 2013; 20(2):111-5. PubMed ID: 23616968
[TBL] [Abstract][Full Text] [Related]
20. Better off blue: BMPR-2 mutation, arteriovenous malformation, and pulmonary arterial hypertension.
Soon E; Southwood M; Sheares K; Pepke-Zaba J; Morrell NW
Am J Respir Crit Care Med; 2014 Jun; 189(11):1435-6. PubMed ID: 24881940
[No Abstract] [Full Text] [Related]
[Next] [New Search]
